These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 38710619

  • 1. Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil.
    Yoshimura Noh J, Inoue K, Suzuki N, Yoshihara A, Fukushita M, Matsumoto M, Imai H, Hiruma S, Ichikawa M, Koshibu M, Sankoda A, Hirose R, Watanabe N, Sugino K, Ito K.
    Endocr J; 2024 Jul 12; 71(7):695-703. PubMed ID: 38710619
    [Abstract] [Full Text] [Related]

  • 2. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
    Wall JR, Fang SL, Kuroki T, Ingbar SH, Braverman LE.
    J Clin Endocrinol Metab; 1984 May 12; 58(5):868-72. PubMed ID: 6200492
    [Abstract] [Full Text] [Related]

  • 3. Comparison of agranulocytosis and anti-neutrophil cytoplasmic antibody-associated vasculitis caused by two antithyroid drugs: A pharmacovigilance study using the WHO international database.
    Han JY, Lee JM, Jung SY, Kim MS, Lee SW, Kronbichler A, Tizaoui K, Koyanagi A, Kim EY, Song K, Chae HW, Yon DK, Shin JI, Smith L.
    Fundam Clin Pharmacol; 2024 Aug 12; 38(4):780-788. PubMed ID: 38342499
    [Abstract] [Full Text] [Related]

  • 4. The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves' disease.
    Tsuboi K, Ueshiba H, Shimojo M, Ishikawa M, Watanabe N, Nagasawa K, Yuasa R, Yoshino G.
    Endocr J; 2007 Feb 12; 54(1):39-43. PubMed ID: 17053291
    [Abstract] [Full Text] [Related]

  • 5. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.
    Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A.
    Thyroid; 2009 Jun 12; 19(6):559-63. PubMed ID: 19445623
    [Abstract] [Full Text] [Related]

  • 6. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
    Kubota S.
    Intern Med; 2016 Jun 12; 55(22):3235-3237. PubMed ID: 27853063
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment.
    Kobayashi S, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Ohye H, Suzuki M, Yoshihara A, Iwaku K, Sugino K, Ito K.
    Thyroid; 2014 May 12; 24(5):796-801. PubMed ID: 24341564
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adverse effects related to thionamide drugs and their dose regimen.
    Werner MC, Romaldini JH, Bromberg N, Werner RS, Farah CS.
    Am J Med Sci; 1989 Apr 12; 297(4):216-9. PubMed ID: 2523194
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism.
    Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A.
    Clin Endocrinol (Oxf); 2001 Mar 12; 54(3):385-90. PubMed ID: 11298092
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
    Huang CN, Hsu TC, Chou HH, Tsay GJ.
    J Formos Med Assoc; 2004 Apr 12; 103(4):274-9. PubMed ID: 15175822
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
    Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N.
    J Clin Endocrinol Metab; 2007 Jun 12; 92(6):2157-62. PubMed ID: 17389704
    [Abstract] [Full Text] [Related]

  • 15. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease.
    Sera N, Ashizawa K, Ando T, Abe Y, Ide A, Usa T, Tominaga T, Ejima E, Yokoyama N, Eguchi K.
    Thyroid; 2000 Jul 12; 10(7):595-9. PubMed ID: 10958312
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Incidence of and Risk Factors for Neonatal Hypothyroidism Among Women with Graves' Disease Treated with Antithyroid Drugs Until Delivery.
    Yoshihara A, Noh JY, Inoue K, Watanabe N, Fukushita M, Matsumoto M, Suzuki N, Suzuki A, Kinoshita A, Yoshimura R, Aida A, Imai H, Hiruma S, Sugino K, Ito K.
    Thyroid; 2023 Mar 12; 33(3):373-379. PubMed ID: 36680759
    [Abstract] [Full Text] [Related]

  • 18. The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.
    Kimura M, Seki T, Ozawa H, Ishihara T, Komatsu M, Tajiri S, Yanagi H, Nishina M, Noh JY, Fukagawa M, Takagi A.
    Endocr J; 2013 Mar 12; 60(3):383-8. PubMed ID: 23154533
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Disproportionality Analysis of the Adverse Effect Profiles of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Using the Japanese Adverse Drug Event Report Database.
    Arai M, Tsuno T, Konishi H, Nishiyama K, Terauchi Y, Inoue R, Shirakawa J.
    Thyroid; 2023 Jul 12; 33(7):804-816. PubMed ID: 37130038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.